Ramón
García Sanz
Profesor Titular de Universidad
Joan
Bargay Lleonart
Publicaciones en las que colabora con Joan Bargay Lleonart (14)
2022
-
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Blood cancer journal, Vol. 12, Núm. 4, pp. 68
2021
-
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma
Blood, Vol. 137, Núm. 1, pp. 49-60
2020
-
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 8, pp. 784-792
-
Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain
Biology of Blood and Marrow Transplantation, Vol. 26, Núm. 8, pp. 1534-1542
2018
2015
-
Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: Results of the randomized AZABACHE Spanish trial
Haematologica, Vol. 100, Núm. 9, pp. 1207-1213
2013
-
Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma: Results from a GEM/PETHEMA study
British Journal of Haematology, Vol. 163, Núm. 5, pp. 581-589
2012
-
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial
Blood, Vol. 120, Núm. 13, pp. 2581-2588
2011
-
Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance
Blood, Vol. 118, Núm. 17, pp. 4547-4553
2010
-
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial
The Lancet Oncology, Vol. 11, Núm. 10, pp. 934-941
-
Utilización de bisfosfonatos en pacientes con mieloma múltiple: recomendaciones del comité de expertos del Grupo Español de Mieloma del Programa Español de Tratamientos en Hematología
Medicina Clinica, Vol. 134, Núm. 6, pp. 268-278
2008
-
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Updated time-to-events results and prognostic factors for time to progression
Haematologica, Vol. 93, Núm. 4, pp. 560-565
2006
-
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase 1/2 study
Blood, Vol. 108, Núm. 7, pp. 2165-2172